2001
Up-regulation of macrophage migration inhibitory factor in acute renal allograft rejection in the rat
Brown F, Nikolic-Paterson D, Metz C, Bucala R, Atkins R, Lan H. Up-regulation of macrophage migration inhibitory factor in acute renal allograft rejection in the rat. Clinical & Experimental Immunology 2001, 118: 329-336. PMID: 10540199, PMCID: PMC1905421, DOI: 10.1046/j.1365-2249.1999.01048.x.Peer-Reviewed Original ResearchConceptsMacrophage migration inhibitory factorMIF mRNA expressionAcute renal allograft rejectionAcute allograft rejectionRenal allograft rejectionAllograft rejectionMigration inhibitory factorDay 5MIF expressionRenal allograftsMRNA expressionDay 1Inhibitory factorLocal MIF productionMIF protein expressionNormal renal functionT-cell infiltratesCell-mediated diseaseSevere tubular damageCellular immune responsesImmune cell-mediated diseasesSevere tubulitisSevere rejectionCreatinine clearanceMIF productionLysozyme Enhances Renal Excretion of Advanced Glycation Endproducts In Vivo and Suppresses Adverse AGE-mediated Cellular Effects In Vitro: A Potential AGE Sequestration Therapy for Diabetic Nephropathy?
Zheng F, Cai W, Mitsuhashi T, Vlassara H, Bucala R. Lysozyme Enhances Renal Excretion of Advanced Glycation Endproducts In Vivo and Suppresses Adverse AGE-mediated Cellular Effects In Vitro: A Potential AGE Sequestration Therapy for Diabetic Nephropathy? Molecular Medicine 2001, 7: 737-747. PMID: 11788787, PMCID: PMC1950004, DOI: 10.1007/bf03401963.Peer-Reviewed Original ResearchConceptsAdvanced glycation endproductsSerum advanced glycation endproductsDb/db miceNon-obese diabeticSerum AGEsMesangial cellsDb miceAGE-BSAGlycation endproductsIGF-I productionDiabetic renal damageSprague-Dawley ratsAGE clearanceSuppress macrophagesNOD miceDiabetic nephropathyRenal damageRenal excretionNormal ratsMMP-9Type IV collagenHost defense proteinsExcretionMRNA levelsMiceURINE MACROPHAGE MIGRATION INHIBITORY FACTOR CONCENTRATIONS AS A DIAGNOSTIC TOOL IN HUMAN RENAL ALLOGRAFT REJECTION1
Brown F, Nikolic-Paterson D, Chadban S, Dowling J, Jose M, Metz C, Bucala R, Atkins R. URINE MACROPHAGE MIGRATION INHIBITORY FACTOR CONCENTRATIONS AS A DIAGNOSTIC TOOL IN HUMAN RENAL ALLOGRAFT REJECTION1. Transplantation 2001, 71: 1777-1783. PMID: 11455258, DOI: 10.1097/00007890-200106270-00013.Peer-Reviewed Original ResearchConceptsMacrophage migration inhibitory factorAcute rejectionMIF concentrationsRenal transplant patientsCyA toxicityTransplant patientsProspective studyRetrospective studyNormal controlsSerum macrophage migration inhibitory factorUrine macrophage migration inhibitory factorAcute renal allograft rejectionStable renal transplant patientsDay 1 posttransplantationEpisodes of biopsyLocal MIF productionRenal allograft patientsRENAL ALLOGRAFT REJECTION1Renal transplant dysfunctionSerum MIF concentrationsSerum MIF levelsTransplant patient groupsRenal allograft rejectionPro-inflammatory cytokinesNormal healthy controls
1998
Reversal of Established Rat Crescentic Glomerulonephritis by Blockade of Macrophage Migration Inhibitory Factor (MIF): Potential Role of MIF in Regulating Glucocorticoid Production
Yang N, Nikolic-Paterson D, Ng Y, Mu W, Metz C, Bacher M, Meinhardt A, Bucala R, Atkins R, Lan H. Reversal of Established Rat Crescentic Glomerulonephritis by Blockade of Macrophage Migration Inhibitory Factor (MIF): Potential Role of MIF in Regulating Glucocorticoid Production. Molecular Medicine 1998, 4: 413-424. PMID: 10780884, PMCID: PMC2230272, DOI: 10.1007/bf03401748.Peer-Reviewed Original ResearchConceptsMacrophage migration inhibitory factorMigration inhibitory factorCrescentic glomerulonephritisDay 7Ab treatmentRenal functionControl AbInhibitory factorPotent pro-inflammatory cytokineEndogenous glucocorticoid levelsIsotype control AbSevere renal injuryNormal renal functionCellular immune responsesPro-inflammatory cytokinesReversal of diseaseSerum corticosterone levelsExperimental crescentic glomerulonephritisInterleukin-1 productionRat crescentic glomerulonephritisCrescentic diseaseProgressive glomerulonephritisRenal injuryGBM glomerulonephritisLeukocyte infiltration
1995
Advanced glycosylation end products in diabetic renal and vascular disease
Bucala R, Vlassara H. Advanced glycosylation end products in diabetic renal and vascular disease. American Journal Of Kidney Diseases 1995, 26: 875-888. PMID: 7503061, DOI: 10.1016/0272-6386(95)90051-9.Peer-Reviewed Original ResearchConceptsAdvanced glycosylation end productsGlycosylation end productsPhase II/III clinical trialsNormal renal functionInactivate nitric oxideSpecific therapeutic modalitiesRenal functionVascular complicationsDiabetic nephropathyGlomerular sclerosisGlucose-derived Amadori productsEtiologic roleVascular diseaseClinical trialsMatrix protein synthesisTherapeutic modalitiesVascular permeabilityAdvanced glycosylationLipoprotein depositionEnd productsTissue toxicityNitric oxidePharmacologic inhibitorsToxicityProtein synthesisImmunohistochemical detection of advanced glycosylation end products within the vascular lesions and glomeruli in diabetic nephropathy
Nishino T, Horii Y, Shiiki H, Yamamoto H, Makita Z, Bucala R, Dohi K. Immunohistochemical detection of advanced glycosylation end products within the vascular lesions and glomeruli in diabetic nephropathy. Human Pathology 1995, 26: 308-313. PMID: 7890283, DOI: 10.1016/0046-8177(95)90063-2.Peer-Reviewed Original ResearchConceptsAdvanced glycosylation end productsGlycosylation end productsSevere diffuse lesionsAnti-AGE antibodyComplications of diabetesInner elastic layerRenal complicationsDiabetic nephropathyAGE antibodyDiffuse lesionsNondiabetic individualsVascular lesionsPathogenic roleAGE accumulationHyaline depositsImmunohistochemical stainingPositive stainingImmunohistochemical detectionAdvanced glycosylationVascular intimaNormal agingSpecific antibodiesTissue distributionEnd productsAntibodies